Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Opioid REMS Proposal Leaves Advisory Panel Wanting More - i.e. Mandatory Training

This article was originally published in The Pink Sheet Daily

Executive Summary

Prior training programs have been much smaller in scope, OND Director John Jenkins points out.
Advertisement

Related Content

Does Mandatory Opioid Prescriber Education Go Far Enough? Congress Might Say No
Opioid REMS Needs Legislation Mandating Physician Training For Full Implementation
Endo Sees Regulatory Setting For Opana ER As "A Moving Target"
Endo Sees Regulatory Setting For Opana ER As "A Moving Target"
The REMS Filibuster: FDA Wants Ability To End Post-Approval Talks, Make Final Decision
Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use
Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use
Alkermes' Vivitrol For Opioid Dependence Could Be Dealt Wild Card At Advisory Committee
If Opioid REMS Mandates Prescriber Training, Firms May Ask DEA For Help
FDA Opts For Education Over Registries in Proposed Opioids REMS

Topics

Advertisement
UsernamePublicRestriction

Register

PS070950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel